Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation.

PubWeight™: 0.95‹?› | Rank: Top 15%

🔗 View Article (PMC 4166963)

Published in Int J Chron Obstruct Pulmon Dis on September 12, 2014

Authors

Alexander G Chuchalin1, Nikolai Khaltaev2, Nikolay S Antonov1, Dmitry V Galkin3, Leonid G Manakov4, Paola Antonini5, Michael Murphy5, Alexander G Solodovnikov6, Jean Bousquet7, Marcelo H S Pereira8, Irina V Demko9

Author Affiliations

1: Institute of Pulmonology, Federal Medical and Biological Agency, Moscow, Russia.
2: Global Alliance Against Chronic Respiratory Diseases (GARD), Genève, Switzerland.
3: GlaxoSmithKline, Moscow, Russia.
4: Far Eastern Scientific Center of Physiology and Pathology of Respiration RAS (Russian Academy of Sciences), Blagoveshchensk, Russia.
5: Worldwide Clinical Trials, King of Prussia, PA, USA.
6: Worldwide Clinical Trials, Ekaterinburg, Russia.
7: Institut National de la Santé et de la Recherche Médicale, Montpellier, France.
8: Research and Development Chief Medical Office, International Medical, GlaxoSmithKline, London, United Kingdom.
9: Krasnoyarsk State Medical University, Krasnoyarsk, Russia.

Articles cited by this

Standardisation of spirometry. Eur Respir J (2005) 48.20

The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy (2004) 13.16

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97

International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet (2007) 10.12

Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med (2004) 8.39

Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03

Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet (2004) 6.17

The global burden of asthma. Chest (2006) 5.74

Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. Lancet (2005) 5.61

Effect of educational outreach to nurses on tuberculosis case detection and primary care of respiratory illness: pragmatic cluster randomised controlled trial. BMJ (2005) 3.84

Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet (1998) 3.56

Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med (2003) 3.05

A randomized clinical trial to reduce asthma morbidity among inner-city children: results of the National Cooperative Inner-City Asthma Study. J Pediatr (1999) 3.03

The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J (2012) 2.79

Interpreting COPD prevalence estimates: what is the true burden of disease? Chest (2003) 2.78

The European Community Respiratory Health Survey: what are the main results so far? European Community Respiratory Health Survey II. Eur Respir J (2001) 2.35

Use of asthma guidelines by primary care providers to reduce hospitalizations and emergency department visits in poor, minority, urban children. J Pediatr (2005) 2.15

A 10 year asthma programme in Finland: major change for the better. Thorax (2006) 2.13

Population impact of different definitions of airway obstruction. Eur Respir J (2003) 2.11

Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax (2003) 2.11

Prevalence and underdiagnosis of COPD by disease severity and the attributable fraction of smoking Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med (2005) 1.89

Prevalence of airways obstruction in a general population: European Respiratory Society vs American Thoracic Society definition. Chest (2000) 1.60

Chronic bronchitis in COPD patients is associated with increased risk of exacerbations: a cross-sectional multicentre study. Int J Clin Pract (2013) 1.58

Economic impact and quality-of-life burden of allergic rhinitis. Curr Med Res Opin (2004) 1.50

Long-term changes in adult asthma prevalence. Eur Respir J (2003) 1.38

Global alliance against chronic respiratory diseases. Allergy (2007) 1.31

Variations in the prevalence across countries of chronic bronchitis and smoking habits in young adults. Eur Respir J (2001) 1.26

Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest (1999) 1.20

Stability of asthma control with regular treatment: an analysis of the Gaining Optimal Asthma controL (GOAL) study. Allergy (2008) 1.20

Allergic Rhinitis and Its Impact on Asthma in Asia Pacific and the ARIA Update 2008. World Allergy Organ J (2012) 1.19

Sex-related differences in COPD in five Latin American cities: the PLATINO study. Eur Respir J (2010) 1.14

The burden of asthma in children: a Latin American perspective. Paediatr Respir Rev (2005) 1.04

Under-report and underdiagnosis of chronic respiratory diseases in an African country. Allergy (2009) 1.03

The burden of allergic rhinitis: beyond dollars and cents. Ann Allergy Asthma Immunol (2002) 1.02

Burden of concomitant allergic rhinitis in adults with asthma. J Asthma (2006) 1.01

Up-to-date on mortality in COPD - report from the OLIN COPD study. BMC Pulm Med (2012) 0.92

Executive summary of the multicenter survey on the prevalence and risk factors of chronic respiratory diseases in patients presenting to primary care centers and emergency rooms in Syria. J Thorac Dis (2012) 0.83

WHO strategy for prevention and control of chronic obstructive pulmonary disease. Exp Lung Res (2005) 0.79